In our experiments, the treatment of SPRED2-deficient BC cells with ulixertinib restored normal ERα protein levels as well as normal (lower) levels of ERK1/2 phosphorylation, and resensitized the cells to tamoxifen. This evidence concerns the gene ESR1 and breast cancer.